ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC50 of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity.
In Vitro Activity
ML-210 exhibits cell-killing activity across a panel of 821 cancer cell lines (WM88, LOX-IMVI, CJM, U257, CAKI2, A498, HT1080, MC38, PANC02). ML-210 is a prodrug that requires cellular activation to bind GPX4.
ML-210 has IC50s of 71 nM, 272 nM and 107nM for BJeLR (HRASV12), BJeH-LT (without HRASV12) and DRD cell lines, respectively.
Storage & Handling
Storage
Powder, -20 °C, 3 years; 4 °C, 2 years
In solvent: -80 °C, 6 months, -20 °C, 1 month.
Shipping
Room temperature in continental US; may vary elsewhere.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.